Christoph Nowak
Chief Tech/Sci/R&D Officer presso DIAMYD MEDICAL AB
Patrimonio netto: 585 $ in data 31/03/2024
Posizioni attive di Christoph Nowak
Società | Posizione | Inizio | Fine |
---|---|---|---|
DIAMYD MEDICAL AB | Chief Tech/Sci/R&D Officer | - | - |
ONCOZENGE AB | Director/Board Member | 09/09/2023 | - |
Independent Dir/Board Member | 09/09/2023 | - | |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Chief Tech/Sci/R&D Officer | - | - |
Storia della carriera di Christoph Nowak
Precedenti posizioni note di Christoph Nowak
Società | Posizione | Inizio | Fine |
---|---|---|---|
Karolinska Institutet | Corporate Officer/Principal | - | - |
Formazione di Christoph Nowak
University of Oxford | Doctorate Degree |
University of Uppsala | Doctorate Degree |
Technische Universität Braunschweig | Graduate Degree |
Statistiche
Distribuzione geografica
Svezia | 6 |
Regno Unito | 2 |
Germania | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 2 |
Graduate Degree | 1 |
Settori
Consumer Services | 5 |
Health Technology | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
DIAMYD MEDICAL AB | Health Technology |
ONCOZENGE AB | Health Technology |
Aziende private | 1 |
---|---|
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Health Technology |
- Borsa valori
- Insiders
- Christoph Nowak
- Esperienza